Savara(US:SVRA) Globenewswire·2025-09-15 19:50Core Viewpoint - Savara Inc. (NASDAQ: SVRA) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its drug MOLBREEVI, which is intended for the treatment of pulmonary alveolar proteinosis [3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 4, 2024, to May 23, 2025 [3]. - Allegations include that Savara failed to disclose critical information about MOLBREEVI's chemistry, manufacturing, and controls, leading to doubts about FDA approval [3]. - The complaint suggests that the delay in regulatory approval could necessitate Savara to raise additional capital [3]. Group 2: Shareholder Actions - Shareholders who purchased SVRA shares during the class period are encouraged to register for the class action and may seek lead plaintiff status [1][4]. - The deadline for shareholders to register is November 7, 2025, and there is no cost to participate [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Group 3: Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].